Abstract
Transient tachypnea of the newborn results from delayed clearance of lung fluid and is a common cause of admission of full term and late preterm infants to neonatal intensive care units. The condition is particularly common after elective cesarean section. Conventional treatment involves supplemental oxygen, withholding enteral feeds and administration of intravenous fluids and antibiotics. Rarely, infants require CPAP and mechanical ventilation. Occasionally some babies develop severe hypoxemia and may require high concentrations of oxygen. The most effective strategy for accelerating reabsorbtion of fetal lung fluid is exogenous glucocorticoids. Potential therapies for TTN must be based on an understanding of the physiology of normal fetal lung fluid clearence at bith. Furosemide, racemic epinephrine and inhaled β-agonists have been studied for possible benefit in TTN. The routine administration of these drugs can not be recommended unless additional data become available.
Keywords: Transient tachypnea, alveolar fluid, furosemide, racemic epinephrine, salbutamol, newborn, lung fluid, preterm infants, intravenous fluids, hypoxemia
Current Pharmaceutical Design
Title:Transient Tachypnea of the Newborn: The Treatment Strategies
Volume: 18 Issue: 21
Author(s): Murat Yurdakok and Eren Ozek
Affiliation:
Keywords: Transient tachypnea, alveolar fluid, furosemide, racemic epinephrine, salbutamol, newborn, lung fluid, preterm infants, intravenous fluids, hypoxemia
Abstract: Transient tachypnea of the newborn results from delayed clearance of lung fluid and is a common cause of admission of full term and late preterm infants to neonatal intensive care units. The condition is particularly common after elective cesarean section. Conventional treatment involves supplemental oxygen, withholding enteral feeds and administration of intravenous fluids and antibiotics. Rarely, infants require CPAP and mechanical ventilation. Occasionally some babies develop severe hypoxemia and may require high concentrations of oxygen. The most effective strategy for accelerating reabsorbtion of fetal lung fluid is exogenous glucocorticoids. Potential therapies for TTN must be based on an understanding of the physiology of normal fetal lung fluid clearence at bith. Furosemide, racemic epinephrine and inhaled β-agonists have been studied for possible benefit in TTN. The routine administration of these drugs can not be recommended unless additional data become available.
Export Options
About this article
Cite this article as:
Yurdakok Murat and Ozek Eren, Transient Tachypnea of the Newborn: The Treatment Strategies, Current Pharmaceutical Design 2012; 18 (21) . https://dx.doi.org/10.2174/1381612811209023046
DOI https://dx.doi.org/10.2174/1381612811209023046 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Treatments for Obesity-Related Hypertension
Current Hypertension Reviews Various Presentations of Preeclampsia at Tertiary Care Hospital of Sindh: A Cross-Sectional Study
Current Hypertension Reviews Should all Hypertensive Patients be Screened for Primary Aldosteronism?
Current Hypertension Reviews Central Arterial Aging and Angiotensin II Signaling
Current Hypertension Reviews Therapeutic Potential of Targeting Protease Activated Receptors in Cardiovascular Diseases
Current Pharmaceutical Design cGMP Signaling, Phosphodiesterases and Major Depressive Disorder
Current Neuropharmacology Behavioral Effects of 2,3-Dihydro- and Oxoisoaporphine Derivatives in Post Stroke-Depressive Like Behavior in Male Balb/c Mice
Current Topics in Medicinal Chemistry Computational Drug Repositioning: A Lateral Approach to Traditional Drug Discovery?
Current Topics in Medicinal Chemistry Cilostazol: A New Drug in the Treatment Intermittent Claudication
Recent Patents on Cardiovascular Drug Discovery Structural and Molecular Tear Film Changes in Glaucoma
Current Medicinal Chemistry Growth Factor Therapy in Atherosclerotic Disease-Friend or Foe
Current Pharmaceutical Design Brain Angiotensin II Involvement in Chronic Mental Disorders
Protein & Peptide Letters Editorial
Current Enzyme Inhibition Vitamin B<sub>12</sub> Deficiency Among the Healthy Jordanian Adult Population: Diagnostic Levels, Symptomology and Risk Factors
Endocrine, Metabolic & Immune Disorders - Drug Targets Targeting the MCP-1/CCR2 System in Diabetic Kidney Disease
Current Vascular Pharmacology Pulmonary Circulation and Pulmonary Function in Neonatal Lung Hypoplasia:Treatment with Corticosteroids
Current Pediatric Reviews Toxicity by NSAIDs. Counteraction by Stable Gastric Pentadecapeptide BPC 157
Current Pharmaceutical Design Resisting the Sun with Vitamin D
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Biochemical Aspects of Nitric Oxide
Current Pharmaceutical Design Statin Attenuates High Glucose-Induced and Angiotensin II-Induced MAP Kinase Activity Through Inhibition of NAD(P)H Oxidase Activity in Cultured Mesangial Cells
Medicinal Chemistry